RNS Number : 3814J
N4 Pharma PLC
24 October 2024

N4 Pharma plc
("N4 Pharma" or the "Company")

New Corporate Presentation and CEO Q&A

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce the publication of a new corporate presentation accompanied by a video update from CEO, Nigel Theobald.

Key points covered in the presentation include N4 Pharma's strategic focus on two key lead programs: N4 101 for Irritable Bowel Disease ("IBD") and ECP 105 for post-surgical scarring prevention, utilising the Company's proprietary delivery technologies, Nuvec® and LipTide™. The Company's aim is to advance preclinical studies and prepare for a Clinical Trial Authorisation ("CTA") / Investigational New Drug ("IND") filing in the coming years, while also pursuing licensing and platform collaboration opportunities.

Investors are invited to submit questions on the presentation via N4 Pharma's investor hub, and CEO Nigel Theobald will address these in a subsequent video. Register and submit questions at:https://investors.n4pharma.com/link/MP7A7e.

The full slide deck is available to view on N4 Pharma's investor hub here:https://investors.n4pharma.com/s/01e7a3

For more information please contact:

N4 Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive Director
Via N4 Pharma Investor Hub
https://investors.n4pharma.com/announcements

SP Angel CorporateFinance LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Tel: +44(0)20 3470 0470

Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
James Pope
Tel: +44(0)20 3657 0050

Investor hub
Engage with us directly at N4 Pharma Investor Hub
Sign up atinvestors.n4pharma.com

About N4 Pharma
N4 Pharma is a pre-clinical biotech company developing unique nucleic acid based products using its patented delivery systems Nuvec® and Liptide®. Its first two products are an oral anti-inflammatory product for IBD and an siRNA to knock down MRTF-B which reduces scarring post Glaucoma surgery. As well as these it is looking to develop further oncology and gene therapy products.

Its novel delivery systems are also available to third parties for licensing to develop their own products in oncology, gene therapy and vaccines for upfront payments, milestone payments and ultimately royalty payments once products reach the market.

It is also seeking partners or investors to take its initial products into phase 1 clinical trials.

For further information on the Company visitwww.n4pharma.comor sign up athttps://investors.n4pharma.com/auth/signup.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAMJBPTMTTTBAI